Calprotectin - A Marker of Mortality in COPD?: Results from a Prospective Cohort Study

Dennis B Holmgaard; Lone Mygind; Ingrid Titlestad; Hanne Birkemose Madsen; Svend Stenvang Pedersen; Ole Hartvig Mortensen; Court Pedersen

doi:10.3109/15412555.2013.781580

Calprotectin - A Marker of Mortality in COPD? Results from a Prospective Cohort Study

Dennis B Holmgaard, Lone Mygind, Ingrid Titlestad, Hanne Birkemose Madsen, Svend Stenvang Pedersen, Ole Hartvig Mortensen, Court Pedersen

Inflammation, Metabolism and Oxidation

8 Citations (Scopus)

Abstract

Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03-2.38) at calprotectin between 100-200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.

Original language	English
Journal	C O P D
Volume	10
Issue number	5
Pages (from-to)	581-587
Number of pages	7
ISSN	1541-2555
DOIs	https://doi.org/10.3109/15412555.2013.781580
Publication status	Published - Oct 2013

Access to Document

10.3109/15412555.2013.781580

https://www.tandfonline.com/doi/pdf/10.3109/15412555.2013.781580?needAccess=true

Cite this

@article{32f724ddf9924f038460c00c5623d86d,

title = "Calprotectin - A Marker of Mortality in COPD?: Results from a Prospective Cohort Study",

abstract = "Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03-2.38) at calprotectin between 100-200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.",

author = "Holmgaard, {Dennis B} and Lone Mygind and Ingrid Titlestad and Madsen, {Hanne Birkemose} and Pedersen, {Svend Stenvang} and Mortensen, {Ole Hartvig} and Court Pedersen",

year = "2013",

month = oct,

doi = "10.3109/15412555.2013.781580",

language = "English",

volume = "10",

pages = "581--587",

journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",

issn = "1541-2555",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Calprotectin - A Marker of Mortality in COPD?

T2 - Results from a Prospective Cohort Study

AU - Holmgaard, Dennis B

AU - Mygind, Lone

AU - Titlestad, Ingrid

AU - Madsen, Hanne Birkemose

AU - Pedersen, Svend Stenvang

AU - Mortensen, Ole Hartvig

AU - Pedersen, Court

PY - 2013/10

Y1 - 2013/10

N2 - Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03-2.38) at calprotectin between 100-200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.

AB - Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03-2.38) at calprotectin between 100-200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.

U2 - 10.3109/15412555.2013.781580

DO - 10.3109/15412555.2013.781580

M3 - Journal article

C2 - 23844942

SN - 1541-2555

VL - 10

SP - 581

EP - 587

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

IS - 5

ER -

Calprotectin - A Marker of Mortality in COPD? Results from a Prospective Cohort Study

Abstract

Access to Document

Fingerprint

Cite this